Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 245.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 245.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\28481295
.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117 Int+J+Mol+Sci
2017 ; 18
(5
): ä Nephropedia Template TP
gab.com Text
Twit Text FOAVip
Twit Text #
English Wikipedia
Inhibiting HDAC1 Enhances the Anti-Cancer Effects of Statins through
Downregulation of GGTase-I? Expression
#MMPMID28481295
Li R
; Gan YH
Int J Mol Sci
2017[May]; 18
(5
): ä PMID28481295
show ga
Hydroxy-methyl-glutaryl-coenzyme A (HMG-CoA) reductase inhibitors, namely
statins, are potential anti-tumor agents. Previously, we showed that a
pan-histone deacetylase (HDAC) inhibitor enhances the anti-tumor effects of the
HMG-CoA inhibitor. However, the underlying mechanisms were not fully understood.
Cancer cell lines (CAL-27 and SACC-83) were exposed to pan-HDAC inhibitor, or
HDAC1 inhibitor, or geranylgeranyl transferase type I (GGTase-I) inhibitor alone
or in combination with statin. Cell viability, apoptosis, migration, and invasion
were assessed by Cell Count Kit-8, 4',6-diamidino-2-phenylindole staining, and
transwell assay, respectively. A xenograft model was used for assessing tumor
growth in vivo. Western blot and real-time PCR were used to assess the expression
of genes. We observed that inhibiting HDAC1 could enhance the anti-tumor effects
of statins both in vitro and in vivo. Inhibiting HDAC1 blocked the statin-induced
upregulation of geranylgeranyl transferase type I? subunit (GGTase-I?), resulting
in an enhancement of the anti-cancer effects of statin. Overexpression of
GGTase-I? or constitutively active RhoA abolished the enhancement by inhibiting
HDAC1 on anti-tumor effects of statins. The HDAC1 inhibitor failed to enhance
cytotoxicity in non-tumor primary cells treated with statin. Inhibiting HDAC1
enhanced the anti-cancer effects of statins through downregulation of GGTase-I?
expression, and thus further inactivation of RhoA. A combination of statin with
HDAC1 or GGTase-I inhibitor would be a new strategy for cancer chemotherapy.
|*Down-Regulation
[MESH]
|Alkyl and Aryl Transferases/*genetics/metabolism
[MESH]
|Animals
[MESH]
|Antineoplastic Agents/administration & dosage/*pharmacology/therapeutic use
[MESH]